**MR-TRYX: Exploiting horizontal pleiotropy to infer novel causal pathways**

Yoonsu Cho1, Philip C Haycock1, Eleanor Sanderson1, Tom R Gaunt1, Jie Zheng1, Andrew P Morris2, George Davey Smith1, Gibran Hemani1

1 MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK  
2 Department of Biostatistics, University of Liverpool, Liverpool, UK.

\*Correspondence and request for reprints: **Gibran Hemani**, MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Oakfield House, Bristol, BS8 2BN, UK. E-mail: [g.hemani@bristol.ac.uk](mailto:g.hemani@bristol.ac.uk).

## **Abstract**

In Mendelian randomization (MR) analysis, variants that exert horizontal pleiotropy are typically treated as a nuisance. However, they could be valuable in identifying novel pathways to the traits under investigation. Here, we developed the MR-TRYX framework, following the advice of William Bateson to “TReasure Your eXceptions”. We begin by detecting outliers in a single exposure-outcome MR analysis, hypothesising they are due to horizontal pleiotropy. We search across thousands of complete GWAS summary datasets in the MR-Base database to systematically identify other (“candidate”) traits that associate with the outliers. We developed a multi-trait pleiotropy model of the heterogeneity in the exposure-outcome analysis due to pathways through candidate traits. Through detailed investigation of several causal relationships, many pleiotropic pathways were uncovered with already established causal effects, validating the approach, but also novel putative causal pathways. Adjustment for pleiotropic pathways reduced the heterogeneity across the analyses.

Mendelian randomization (MR) is now widely used to infer the causal influence of one trait (the exposure) on another (the outcome) 1, 2. It is generally performed by obtaining genetic instruments for an exposure through genome-wide association studies (GWAS). If the instruments are valid, in that they are unconfounded and influence the outcome only through the exposure (vertical pleiotropy), then they will each provide an independent, unbiased estimate of the causal effect of the exposure on the outcome 3. Meta-analysing these estimates can provide a more precise estimate of the causal relationship between the exposure and the outcome 4, 5. If, however, some of the instruments are invalid, particularly because they additionally influence the outcome through pathways that bypass the exposure (horizontal pleiotropy) 3, then the causal effect estimate is liable to be biased. To date, MR method development has viewed horizontal pleiotropy as a nuisance that needs to be factored out of the analysis 6, 7, 8, 9. Departing from this viewpoint, here we exploit horizontal pleiotropy as an opportunity to identify new traits that putatively influence the outcome. We also explore how this knowledge can improve the original exposure-outcome estimates.

A crucial feature of MR is that it can be performed using only GWAS summary data, where the causal effect estimate can be obtained solely from the association results of the instrumental single nucleotide polymorphisms (SNPs) on the exposure and on the outcome 5. This means that causal inference between two traits can be made even if they have never been measured together in the same sample of individuals. Complete GWAS summary results have now been collected from thousands of complex trait and common diseases 10, meaning that one can search the database for candidate traits that might be influenced by SNPs exhibiting possible pleiotropic effects (outliers). In turn, the causal influence of each of those candidate traits on the outcome can be estimated using MR by identifying their instruments (which are independent of the original outlier). Should any of these candidate traits putatively associate with the outcome then this goes some way towards explaining the horizontal pleiotropic effect that was exhibited by the outlier SNP in the initial exposure-outcome hypothesis.

Several methods exist for identifying outliers in MR, each likely to be sensitive to different patterns of horizontal pleiotropy. Cook’s distance can be used to measure the influence of a particular SNP on the combined estimate from all SNPs 11, identifying SNPs with large influences as outliers. Steiger filtering removes those SNPs that do not explain substantially more of the variance in the exposure trait than in the outcome, attempting to guard against using SNPs as instruments that are likely to be associated with the outcome through a pathway other than the exposure 12. Finally, meta-analysis tools can be used to evaluate if a particular SNP contributes disproportionately to the heterogeneity between the estimates obtained from the set of instruments, and this has been adapted recently to detect outliers in MR analysis 13, 14, 15. A potential limitation of heterogeneity-based outlier removal is that this practice could constitute a form of cherry picking 9, 16. While outlier removal can certainly improve power by reducing noise in estimation, it could also potentially induce higher type 1 error rates, which we go on to explore through simulations.

Recent large-scale MR scans have indicated that horizontal pleiotropy is widespread based on systematic analysis of heterogeneity 15, 17. This suggests that many SNPs used as instruments are likely to associate with other traits, which in turn might associate with the original outcome of interest – hence giving rise to heterogeneity. As such we have an opportunity to identify novel pathways through exploiting outliers. Equipped with automated MR analysis software10, outlier detection methods and a database of complete GWAS summary datasets, we developed MR-TRYX (from the phrase coined by William Bateson, “Treasure your exceptions18”), a framework for identifying novel putative causal factors when performing a simple exposure-outcome analysis. In this paper we present simulations to show how knowledge of horizontal pathways can be used to discover novel putative causal factors for an outcome of interest, and to also improve the power and reliability of the original exposure-outcome association analysis. We apply MR-TRYX to several exemplar analyses to demonstrate its potential utility.

## **Methods**

### Overview of MR-TRYX

Figure 1 shows an overview of the approach. MR-TRYX is applied to an exposure-outcome analysis in two sample MR approach and it has two objectives. The first is to use outliers in the original exposure-outcome analysis to identify novel putative factors that influence the outcome independently of the exposure. The second is to re-estimate the original exposure-outcome association by adjusting outlier SNPs for the horizontal pleiotropic pathways that might arise through the novel putative associations. This outlier-adjustment method should be treated as a new approach to be used in conjunction with other methods that already exist in the MR sensitivity analysis toolkit. We provide extensive discussion on the context, advantages and potential pitfalls that come with trying to use a data-driven approach to adjust for horizontal pleiotropy at the end of the paper.

### Outlier detection

Several outlier detection methods now exist that are based on the contribution of each SNP to overall heterogeneity in an inverse-variance weighted (IVW) meta-analysis 19. In order to estimate heterogeneity accurately, it is important to appropriately weight the contribution of each SNP to the overall estimate. We used the approach implemented in the RadialMR R package (<https://github.com/WSpiller/RadialMR>) to detect outliers. Full details are provided elsewhere 20, but briefly, we used the so-called ‘modified 2nd order weighting’ approach to estimate total Cochran’s Q statistic as a measure of heterogeneity, as well as the individual contributions of each SNP, *qi* 20. This has been shown to be comparable to the simulation-based approach in MR-PRESSO, providing a well-calibrated test statistic for outlier status whilst being computationally more efficient 15, 21. The probability of a SNP being an outlier is calculated based on *qi* being chi-square distributed with 1 degree of freedom. For demonstration purposes we adopted a conservative p-value threshold for identifying outliers, dividing 0.05 by the number of SNPs as a correction for multiple testing. We are not, however, suggesting that this arbitrary threshold will necessarily be optimal for identifying outliers, and users can apply other approaches or thresholds through the MR-TRYX software.




### Candidate trait detection

Traits associated with the detected outliers could causally influence the outcome. MR-TRYX searches the MR-Base database to identify the traits that have associations with the detected outliers. By default, we limit the search to traits for which the GWAS results registered at MR-Base have more than 500,000 SNPs and sample sizes exceeding 5,000. Traits that have an association with outlier SNPs at genome-wide p-value threshold (p < 5 x 10-8; in keeping with traditional GWAS thresholds used for instrument selection) are regarded as potential risk factors for the outcome and defined as “candidate traits”. Each candidate trait is tested for its influence on the original exposure and outcome traits (Figure 1) using the IVW random effects model. We take forward putative associations based on false discovery rate (FDR) < 0.05, where the null hypothesis is true, but we note that the use of arbitrary thresholds is problematic 22, 23, and we use them here to make high dimensional investigations more manageable.

### Assessing causal estimates of the association of candidate traits with the outcome


Once candidate traits are detected, we can identify instruments specifically for the candidate traits and model how the exposure and candidate traits together associate with the outcome. This involves the following process, which we go on to describe in full detail below:


1. Identify instruments for the candidate traits
2. Estimate the influence of the candidate traits on y conditioning on x using multivariable MR


Suppose we have [](about:blank) instruments for the exposure [](about:blank) where [](about:blank) is an outlier in the x-y MR analysis due to an association with candidate trait [](about:blank), where *E* indicates the number of genetic variants for the exposure. Also, [](about:blank) has [](about:blank) genetic instruments, where *M* is the number of genetic variants for . To obtain the estimate of [](about:blank) uncontaminated by shared genetic effects between [](about:blank) and [](about:blank) (Figure 1A), we perform multivariable MR analysis 24. We generate a combined list of instruments for both [](about:blank) and [](about:blank) and clump them to obtain a set of independent SNPs. The original outlier is removed from amongst these SNPs. We then obtain the genetic effects of each of these SNPs on the exposure [](about:blank), candidate trait [](about:blank), and outcome [](about:blank). Finally, we estimate the causal influence of [](about:blank) on [](about:blank) conditioning on [](about:blank) by regressing [](about:blank) weighted by the inverse of the variance of the [](about:blank) estimates. The whole process is automated within the TwoSampleMR R package which connects to the MR-Base database.


In the case of an outlier SNP associating with many candidate traits we first apply a modified form of multivariable MR, involving LASSO regression of [](about:blank) and use cross validation to obtain the shrinkage parameter that minimises the mean squared error. We retain only the candidate traits that are putatively associated with the outcome and have non-zero effects after shrinkage. Then we apply remaining traits in a multivariable model with [](about:blank) against the outcome, as described above 24. We perform the LASSO step because many traits in the MR-Base database have considerable overlap and redundancy, and the statistical power of multivariable analysis depends on the heterogeneity between the genetic effects on the exposure variables 24. Using LASSO therefore automates the removal of redundant traits. With the remaining traits we then obtain estimates of [](about:blank) that are conditionally independent of *x* and amongst all *P* traits by combining them in a multivariable analysis on the outcome [](about:blank). A detailed discussion of dealing with multiple candidate traits per outlier SNP is presented in Supplementary Note 1.


### Adjusting exposure-outcome associations for known candidate-trait associations

An illustration of how outliers arise in MR analyses is shown in Figure 1. If a SNP [](about:blank) has some influence on exposure [](about:blank), and [](about:blank) has some influence on outcome [](about:blank), the SNP effect on [](about:blank) is expected to be [](about:blank), where [](about:blank) is the SNP effect on [](about:blank) and [](about:blank) is the causal effect of [](about:blank) on [](about:blank). Any substantive difference between [](about:blank) and [](about:blank) could be due to an additional influence on [](about:blank) arising from the SNP’s effect through an alternative pathway.


If a SNP influences a ‘candidate trait’, [](about:blank), which in turn influences the outcome (or the exposure and the outcome), then the SNP’s influence on the exposure and the outcome will be a combination of its direct effects through [](about:blank) and indirect effects through [](about:blank) 24. If we have estimates of how the candidate trait influences the outcome, then we can adjust the original SNP-outcome estimate to the effect that it would have exhibited had it not been influencing the candidate trait. In other words, we can obtain an adjusted SNP-outcome effect conditional on the ‘candidate-trait – exposure’ and ‘candidate-trait – outcome’ effects. If the SNP influences [](about:blank) independent candidate traits (as selected from the LASSO step), then the expected effect of the SNP on [](about:blank) is

[](about:blank)

Hence, the effect of the SNP on the outcome adjusted for alternative pathways [](about:blank) is

[](about:blank)

We use parametric bootstraps to estimate the standard error of the [](about:blank) estimate, where 1000 resamples of [](about:blank), [](about:blank) and [](about:blank) are obtained based on their respective standard errors and the standard deviation of the resultant estimate, represents its standard error. Finally, an adjusted effect estimate of [](about:blank) due to SNP [](about:blank) is obtained through the Wald ratio.

[](about:blank)

Occasionally it might be possible that a candidate trait P is a redundant trait for y, for example if the outcome is coronary heart disease, the outliers might detect traits such as ‘medication for heart disease’ as a potential candidate trait. It would make no sense to attempt to adjust the SNP-outcome association for a trait that is essentially the same as the outcome, it would just nullify the association. We have not yet developed an automated method to remove such traits, but we recommend manually checking any traits that are selected for automated outlier adjustment.

### Simulations

IVW effect estimates are liable to be biased when at least some of the instrumenting SNPs exhibit horizontal pleiotropy, and those SNPs tend to contribute disproportionately towards the heterogeneity in the effect estimate. We conducted simulations to evaluate how different methods perform at estimating the causal effect of *x* on *y* under different circumstances. The simulations are principally designed to evaluate the potential value of adjusting outliers for putative explanatory pathways. Other aspects of the MR-TRYX framework, for example dealing with redundant traits in the GWAS database are dealt with separately (Supplementary note 1). In all circumstances there are 30 independent genetic effects on *x* (*Gx*), and *x* either has no direct influence on *y*, or has a direct effect of 0.1 on *y*. For all simulations, we used 10,000 individuals, and repeated each circumstance 1,000 times. We summarised each scenario in two ways: a) We estimated the proportion of simulations that gave a biased estimate of the causal effect of x on y (bxy). For each simulation we calculated the probability of the effect estimate being substantially different from the true simulated effect based on whether the true effect fell outside the 95% confidence interval of the estimate. Then for the set of 1,000 simulations, we calculated the proportion of estimates that were ‘unbiased’. b) We summarised the power and FDR by estimating the area under the receiver operator curve (AUROC), characterising the sensitivity and specificity of each method at determining whether the true causal effect estimate was null or non-null. Each simulation is conducted by first simulating data to satisfy the parameters described below. We then search for instruments for x across all simulated genetic variants and retain those that are significant after Bonferroni correction, and applying the summary data-based methods based on the genetic associations for the instruments on x and y. All genetic variants are simulated to be Hardy Weinberg equilibrium with allele frequency of 0.5.

We investigated three scenarios that could give rise to invalid instruments (Figure 2):

**Confounding pleiotropy**. A confounder, 1, influences *x* and *y*. Here 1 also has a set of independent genetic influences, G1, which may be detected as instruments for *x*.

Parameters:

values are sampled for each SNP from a normal distribution such that they explain 60% of the variance in 1 . The value of is chosen such that 1 explains 60% of the variance in *x* and 40% of the variance in *y*. The values of are sampled from a normal distribution for each of SNPs such that they explain 20% of the variance in *x*. The causal effect is set to either 0, or some value such that *x* explains 10% of the variance in *y*. Values for , , and are sampled from normal distributions with mean 0 and variances that are scaled to satisfy the variances of all other parameters described for the model. Different sets of simulations are run with different proportions of invalid instruments by simulating different numbers of genetic variants directly influencing 1 or *x*:

**Horizontal pleiotropy.** Hereat least some of the instruments for *x* have an independent effect on y that is mediated through some other pathway that does not include *x*. In these simulations, the pleiotropic influence of each instrument, *Gx,i*, is mediated by a different trait, 2,i

Parameters:

Some number of 30 G*x* instruments for *x* are selected to have pleiotropic effects, such that they influence *y* each mediated by an independent trait which itself has its own set of 30 direct genetic influences . The values for the genetic effects on are sampled from a normal distribution such that they explain 20% of the variance in . Each pleiotropic *Gx,i* instrument has an influence on that explains 20% of its variance (. The influence of each on y is such that is normally distributed with mean 0 and variance 0.4. The outcome y is also influenced by *x* where the causal effect is set to either 0, or some value such that *x* explains 10% of the variance in *y*. Values for , , and are sampled from normal distributions with mean 0 and variances that are scaled to satisfy the variances of all other parameters described for the model.

**Mediation pleiotropy**. Here the influence of *x* on *y* is at least partially mediated by another trait u3, and at least some of the instruments for *x* have an independent pleiotropic influence on u3

Parameters:

Some number of 30 *Gx* instruments for *x* are selected to have pleiotropic effects, such that they influence *u3* which itself mediates an effect from *x* to *y*, and has its own set of 30 direct genetic influences . The values for the genetic effects on are sampled from a normal distribution such that they explain 20% of the variance in . Each pleiotropic *Gx,i* instrument has an influence on such that are sampled from a normal distribution explaining 20% of the variance in *u3* in total. The indirect influence of *x* on *y* is generated such that *x* explains 30% of the variance in , and explains 40% of the variance of *y*. The outcome y may also be influenced directly by *x* where the causal effect is set to either 0, or some value such that *x* explains 10% of the variance in *y*. Values for , , and are sampled from normal distributions with mean 0 and variances that are scaled to satisfy the variances of all other parameters described for the model.

In these simulations we ask: if we can identify the pathway through which an outlier SNP has a horizontal pleiotropic effect, can adjustment for that pathway improve the original exposure-outcome analysis? We assess the performance of the following methods for each simulation.

1. *Raw*, where all detected instruments are used in a standard IVW random effects analysis.
2. *Adjusted SNP-outcome effects*
   1. where outlier SNPs are tested for association with all candidate traits and adjusted for the effect of the candidate trait on the outcome using MR-TRYX.
   2. where attempts are made to adjust all detected instruments regardless of outlier status
3. *Removed instruments*
   1. where all detected outliers are removed
   2. where only outliers that are found to influence a candidate trait are removed.
4. *Multivariable MR (MVMR)*
   1. where the traits selected to be included in the model are the candidate traits associated with outliers
   2. where the traits selected to be included in the model are the candidate traits associated with any of the detected instruments regardless of outlier status

### Empirical analyses

As applied examples, we chose two robust findings and two controversial findings that are potentially biased due to pleiotropy: i) systolic blood pressure (SBP) and coronary heart disease (CHD); ii) urate and CHD; iii) sleep duration and schizophrenia; and iv) education level (years of schooling) and body mass index (BMI). Those examples were chosen based on previous findings 25, 26, 27, 28 to illustrate how pleiotropic variants can be used to identify other pathways and adjusted to estimate the causal effect of the original exposure on the outcome independent of pleiotropic bias.

Summary statistics (beta coefficients and SEs) for the associations of the SNPs with each exposure were obtained from the publicly available GWAS database (Supplementary Table S1). Selected SNPs were harmonised for the analysis, excluding palindromic SNPs and pruning for linkage disequilibrium (r2 <0.001). We primarily used the two-sample MR IVW method to obtain causal estimates between exposures and outcomes allowing each SNP to have different mean effect (random effects model). A number of sensitivity analyses were applied to evaluate the consistency of causal effect estimates under different models of pleiotropy amongst the SNPs, including the MR-Egger6, weighted median and weighted mode approaches 7, 8.

Outliers were detected among the instruments for each exposure (P < 0.05 / the number of SNPs). We searched the MR-Base database to identify the candidate traits that are associated with outliers (p < 5 x 10-8). We then performed multivariable MR analysis to test which candidate trait can explain the heterogeneity in the original exposure-outcome association. To perform multivariable MR, more SNPs that instrument the candidate traits were introduced into the analysis.

Subsequently we re-estimated the association of the original exposure and the original outcome using different sets of instruments: a) all SNPs (corresponding to the raw method in our simulation), b) outliers adjusted c) all outlier removed, c) candidate outliers removed.

All analyses were conducted with the TwoSampleMR package of MR-Base (<https://github.com/MRCIEU/TwoSampleMR>) and the MR-TRYX package (https://github.com/explodecomputer/tryx) in R statistical software (ver 3.4.1). Detailed information and the scripts used for the simulations and empirical analyses can be found here <https://github.com/explodecomputer/tryx-analysis>.

## **Results**

### Simulations

We performed a wide range of simulations (Figure 2) to evaluate how a variety of methods designed to deal with pleiotropy fare under a set of different scenarios that violate the exclusion restriction principle. Perhaps the most striking result from these simulations is that no method is always reliable, and several methods are similar over reliability whilst performing very differently from each other between specific scenarios. Across 47 simulation scenarios, adjusting for detected outliers using the MR-TRYX framework had the highest average rank, and simply performing IVW random effects was most often the best performing method, whereas removing detected outliers had the lowest average rank. We found that as the proportion of instruments exhibiting pleiotropic effects increased, all methods typically worsened in their performance though there were notable examples in which increasingly widespread pleiotropy doesn’t have an adverse effect. For example, widespread balanced horizontal pleiotropy or mediated pleiotropy does not have a drastic adverse influence on IVW, and MVMR and outlier adjustment is relatively impervious to confounding pleiotropy.

It is an obvious conceptual disadvantage in these simulations for some methods (e.g. IVW and outlier removal) that use only the exposure and outcome data, against MVMR and MR-TRYX which draw on information from other sources. However, we note that the MR-TRYX adjustment approach depends on detecting candidate traits that explain the pleiotropic effect and if the relevant candidate traits are not available, there is no adjustment and the method becomes identical to random effects IVW which generally performs better than outlier removal. We also note that if we use association with candidate traits to determine whether or not to remove an outlier then improvements can be made over simple outlier removal. What we observe here is intuitive because the potential drawback of outlier removal is that the outliers could be the only valid instruments, or false discovery rates increase due to overly precise confidence intervals. Thus, adding an extra barrier to the removal of outliers can mitigate these problems.

Multivariable MR performs generally well except in the case when the candidate trait is a mediator of the x-y association, in which case it performs extremely poorly because it adjusts for the entirety of x's signal on y. This result is indistinguishable from an alternative model in which x's effect being nullified due to its univariate effect being driven by pleiotropy29. Adjusting for outliers escapes this problem to some extent because it only adjusts some proportion of the instruments for x that are most likely to be pleiotropic, allowing any true x-y association to persist due to the unadjusted variants.

### Empirical MR-TRYX analyses using four exposure-outcome hypotheses

##### To examine the performance of MR-TRYX analysis, we tested four independent exposure-outcome hypotheses. For each analysis we: a) obtain MR estimates of the exposure-outcome causal relationship and detect outlier instruments; b) identify putative novel influences (candidate traits) on the outcome trait based on their associations with outlier variants (Table 1; Supplementary Table S2); c) adjust the original SNP-outcome estimates for the putative influences operating through the candidate traits (Table 2); and d) compare the changes in heterogeneity in the MR estimates of the adjusted SNP-outcome effects to standard outlier removal methods (Figure 4).

##### Example 1: Systolic blood pressure and coronary heart disease

Blood pressure is a well-established risk factor for CHD. Random effects IVW estimates indicated that higher SBP is causally associated with higher risk of CHD (Odds ratio [OR] per 1SD: 1.76; 95% CI: 1.47, 2.10). While there was substantial heterogeneity in this estimate (Q=682.7 on 157 SNPs, p=5.74 x 10-67), the estimates from MR Egger, weighted median and weighted mode methods were consistent (Table 2). Seven of the 157 SNPs were detected as strong outliers based on Q statistics. We identified 69 candidate traits that were associated with these outliers (p < 5 x 10-8). We manually removed redundant traits and traits that are similar to the exposure and the outcome (e.g. high blood pressure). Among the candidate traits, 15 were putatively causally associated with the risk of CHD (Figure 3A). After we applied LASSO regression, 6 traits remained (Table 1): Anthropometric measures (e.g. height), lipid levels (e.g. cholesterol level), and self-reported ibuprofen use were amongst the candidate traits that associated with CHD, which were uncovered due to two outliers (rs3184504 near *SH2B3* and rs9349279 near *PHACTR*).

We next adjusted the exposure-outcome association for the detected pleiotropic pathways and obtained an adjusted IVW estimate. The total heterogeneity, based on adjusting only these two of 157 SNP effects, was reduced by 17% (Q=567.6). The effect estimate remained consistent with the original estimate, as did the IVW estimates when removing all outliers, or just outliers known to associate with candidate traits that associated with the outcome. However, the width of the confidence interval was substantially larger (including the null) after removing outliers known to associate with candidate traits (1 OR per SD: 1.80; 95% CI: 0.56, 5.79).

##### Example 2: Urate and coronary heart disease

Here we show an example with mixed findings from previous studies. The influence of circulating urate levels on risk of coronary heart disease has been under debate. Several MR studies have investigated the inflated effect of urate on CHD, which appeared to be influenced by pleiotropy 26 30. We re-estimated the associations here using a range of MR methods. As has been previously reported the estimate from IVW suggested a weak association between urate and the risk of CHD using all variants (OR per 1 SD: 1.08; 95% CI: 1.00, 1.17), while there was a large intercept in the MR-Egger analysis (intercept = 1.02; 95% CI: 1.00, 1.03) with a much-attenuated causal effect estimate (Table 2). The median and mode-based estimates were also consistent with the MR-Egger estimate, indicating weak support for urate having a causal influence on CHD. Three variants were detected as outliers, which associated with 61 candidate traits (p < 5 x 10-8). Among those outliers, rs653178, and rs642803 were associated with 14 traits that had conditionally independent influences on the outcome (Figure 3B), including anthropometric measures (e.g. hip circumference), cholesterol levels, diagnosis of thyroid disease, and smoking status.

Removing the outliers in the IVW analysis led to a more precise (though slightly attenuated) estimate of the influence of higher urate levels on CHD risk (OR per 1 SD: 1.05; 95% CI: 1.01, 1.10 and OR per 1 SD: 1.06, 95% CIs: 1.06, 1.12, respectively, Table 2). The adjustment model also indicated an attenuated IVW estimate in comparison to the ‘raw’ approach, with confidence intervals spanning the null (OR per 1 SD: 1.07, 95% CI: 0.99, 1.16) whilst the degree of heterogeneity was reduced by half by accounting for the pleiotropic pathways through two outlier SNPs. The adjusted scatter plot showed that outliers moved towards the fitted line after controlling for the SNP effect on the candidate traits (Figure 4B). The results in this analysis suggest that it is unlikely that urate has a strong causal influence on CHD. Here, outlier removal appears to strengthen evidence that may lead to wrong conclusion.

##### Example 3: Sleep duration and schizophrenia

Previous studies have shown that sleep disorder is associated with schizophrenia 28. However, none of them confirmed the causality between sleep disorder and schizophrenia.

We observed weak evidence for any association between sleep duration and schizophrenia (OR per 1 SD: 1.18; 95% CIs: 0.57, 2.45), but there was substantial heterogeneity when all SNPs were used (Q= 204.8, p=6.9 x 10-26). Six outlier instruments were detected, which associated with 46 candidate traits (p < 5 x 10-8). Among those outliers, the SNPs rs7764984 (near *HIST1H2BJ)* and rs13107325 (near *SLC39A8)* were associated with three traits that putatively influenced the outcome: self-reported coeliac disease, body composition (impedance of leg) and memory function (Figure 4C).

We re-estimated the original association accounting for the detected outliers. The degree of heterogeneity was reduced by 74% (Q=54.1) when removing all 6 outliers and by 46% (Q=147.7) when adjusting for the two SNP effects that had putative pleiotropic pathways. Both methods of outlier removal and adjustment provide similar estimates in terms of direction, whilst the magnitude of estimates differed. After removing outliers, MR Egger causal estimates were substantially larger (OR per 1 SD= 2.43; 95% CI: 0.49, 12.16 and Beta= 0.20; 95% CI: -0.40, 0.79, respectively) than those from the method using all variants. IVW causal estimates from the adjustment method were virtually identical with the original estimates, with narrower CIs (OR per 1 SD= 2.36; 95% CI: 0.25, 21.96). While all methods indicate that sleep duration is unlikely to be a major causal risk factor for schizophrenia, pursuing outliers in the analysis provided putative indications that coeliac disease and memory function may be risk factors for schizophrenia (Figure 4D).

Example 4: Years of schooling and body mass index

The association of education and health outcome is well established in social science 31. Higher socioeconomic position is generally thought to lead to a lower risk of obesity in high-income countries32, 33. We used 59 independent genetic instruments 34 to estimate the influence of years of schooling on BMI 35 (Table 2). All MR methods indicated that years of schooling has a causal beneficial effect on BMI (e.g. IVW Beta: -0.27; 95% CI: -0.39, -0.16), except the estimate from MR Egger which had a very imprecise estimate (beta: 0.01; 95% CI: -0.67, 0.70), but the degree of heterogeneity was large (Q = 211.9 on 59 SNPs; p=2.20 x 10-8). Three outliers (rs6882046 near *LINC00461*, rs4800490 near *NPC1*, rs8049439 near *ATXN2L*) were identified as contributors to heterogeneity, and they showed associations (p < 5 x 10-8) with 48 candidate traits. Among those candidate traits, two were associated with BMI (Figure 3B): alcohol intake frequency (which associated with all three outliers) and usual walking pace.

We next re-estimated the influence of years of schooling on BMI by accounting for outliers. Adjusting the outliers for candidate trait pathways such as alcohol intake and usual walking pace reduced heterogeneity by 15% and had a small reduction in the confidence intervals while the point estimate remained consistent (Table 1). By contrast, there was a 48% reduction in heterogeneity when removing outliers. Point estimates remained largely consistent across all outlier removal methods. However, we note that Figure 4B shows that one of the outliers (rs4800490, near gene *NPC1*) on the scatter plot moved away from the fitted line after adjusting for the pleiotropic pathway, indicating that if this outlier is due to a pleiotropic pathway we have estimated its indirect effect inaccurately or partially (e.g. where GWAS summary statistics are not available to identify other effective pleiotropic pathways).

## **Discussion**

The problem of instrumental variables being invalid due to horizontal pleiotropy has received much attention in MR analysis. Detecting and excluding such invalid instruments, based on whether they appear to be outliers in the analysis, is now a common strategy that exists in various forms 7, 8, 14, 15, 36. We have shown here that outlier removal could, in some circumstances, compound rather than reduce bias, and misses an opportunity to better understand the traits under study. We developed the MR-TRYX framework, which utilises the MR-Base database 10 of GWAS summary data to identify potential explanations for outlying SNP instruments, and to improve estimates by accounting for the pleiotropic pathways that give rise to them. We have also demonstrated the use and interpretation of MR-TRYX in four sets of empirical analyses.

For accurate performance, MR-TRYX depends upon the performance of three methodological components: (i) detecting instruments that exhibit horizontal pleiotropy; (ii) identifying the candidate traits on the alternative pathways from the variant to the outcome; and (iii) adequately estimating the effects of the candidate traits on the outcome. Each of these components is a difficult problem, but they are all modular and build upon existing methods and resources, and the MR-TRYX framework will naturally improve as those methods and resources themselves improve. We will now discuss the consequences of underperformance of each of these components on the TRYX analysis.

First it is important to notice that a major motivation for development of MR is that observational associations are often deemed unreliable because it is impossible to prove that there is no residual or unmeasured confounding biasing the effect estimate. But somewhat ironically, we find ourselves in a situation now where horizontal pleiotropy poses a similar challenge, in that proving that it is either absent or perfectly balanced is impossible. Some methods exist that attempt to adjust for horizontal pleiotropy, such as multivariable MR37, by including in the same model the genetic effects on one or more traits that are hypothesised to mediate the horizontal pleiotropic pathways, which depends upon those pathways being identified. While clearly not a panacea for MR analysis, it is a valuable method to be included within the MR toolkit, and its efficacy has been demonstrated. However, there is another important issue with multivariable MR in that it fails to distinguish between a pleiotropic model where the exposure (X) doesn’t influence the outcome (Y) but has instruments that associate with another trait (A) which does influences Y, versus a causal model in which trait A mediates the causal effect of X on Y. In both situations X will be deemed to be non-causal, despite it being truly causal in the latter case. This issue is discussed in detail in elsewhere 29. Here, MR-TRYX improves on the matter because instead of adjusting all instruments for the mediator, only the outlier variant is adjusted. Thus, the risk of erroneously removing all instrument effects is replaced by the lesser risk of incorrectly adjusting for the bias due to a minority of outliers.

The classification of an outlier in MR analysis can be based on the statistical estimates of how a SNP being included as an instrument due to being reverse causal (Steiger filtering) 12, 17, the extent to which a single SNP disproportionately influences the overall result (e.g. Cook’s distance) 38, or most commonly the extent to which a SNP contributes to heterogeneity (e.g. Cochran’s Q statistic, MR-PRESSO, and implicitly in median- and mode-based estimators) 7, 8, 14, 15. The philosophy of the latter two approaches is that proving horizontal pleiotropy is impossible, but that it should lead to outliers 9. While a useful approximation, these approaches have two main limitations. First, determining whether a SNP is an outlier depends on the use of arbitrary thresholds, and this entails a trade-off between specificity and sensitivity. Second, if most variants are pleiotropic, then it is possible that the outlier SNPs are the only valid instruments. Such a scenario can arise for complex traits such as gene expression or protein levels that have a few large effects and many small effects. For example, for C-reactive protein (CRP) levels, the SNP in the *CRP* gene region is likely the only valid instrument in some analyses 39. In this context, bias due to horizontal pleiotropy cannot be avoided by selection of instruments since this approach may generate more bias 40. This is supported by our simulation which demonstrates that in the presence of extensive pleiotropy removing outliers increased FDR and bias.

MR-TRYX should, in principle, avoid the problem of outlier removal because instead of removing outliers in their entirety, it attempts to eliminate the component of the SNP-outcome effect that is due to horizontal pleiotropy. Hence, we avoid implicitly cherry picking from amongst the SNPs to be used in the analysis, and if we have low sensitivity (i.e. a more relaxed threshold for outlier detection) it doesn’t mean that there will be an unnecessary loss of power in the overall analysis. Previous work has adjusted for the effect of pleiotropic phenotypes, but they treated pleiotropic phenotypes as exogenous variables that are not associated with the causal pathways of interest 41. In MR-TRYX, candidate traits are treated as endogenous variables to account for the effect of the traits on the original association. Moreover, our method is applicable in the two-sample context, whereas the previous method requires individual level data. The problem of outlier detection which remains in MR-TRYX could be sidestepped by applying the adjustment approach to all SNPs irrespective of their contributions to heterogeneity.

Upon identification of potentially pleiotropic SNPs, MR-TRYX can only account for these if the pathways through which pleiotropy is acting can be identified. Detecting the pathways depends on the density and coverage of the human phenome available for the analysis. We use the MR-Base database of GWAS summary results, which comprises several hundred independent traits (605 traits from UK Biobank and 342 other complex traits and diseases obtained from previous GWA studies). While a valuable resource, it is certainly not covering the whole human phenome, and therefore even if a pleiotropic variant is detected correctly, it may not be possible to adjust it away. In the empirical analyses, often fewer than half of the candidate traits were inferred to be associated with the outcome. Also, MR-Base database is currently biased towards discovery GWAS, with few results from replication studies. Yet, as we illustrated, MR-TRYX allows for an informative analysis that could routinely be applied in MR analyses. Broadening phenotype coverage is an on-going pursuit that will continually improve MR-TRYX analysis 42.

MR-TRYX is an expansive framework and there are several limitations in addition to those discussed already. First, our LASSO extension to multivariable MR is used to automate the selection of exposures that will be used for adjustment. A shrinkage step of LASSO may increase the SNP-exposure effect heterogeneity, which is necessary to assess the power of multivariable MR 24. Multivariable MR is adept at establishing conditionally independent exposures but the reason that some exposures have attenuated effects in comparison to their total effects could be because of a) their total effects were biased by pleiotropy or b) they are mediated by the exposures that are included in the model. Interpretations of a) and b) are very different, because in the case of mediation the exposure is a causal factor for the outcome. Second, we were primarily using the multivariable approach for practical purposes to avoid having multiple highly related exposures taken forward to the adjustment step (e.g. multiple different measures of body composition such as body weight and BMI). This approach worked effectively, although a problem remains unsolved in automating the removal of traits that are “similar” to the outcome. For example, if a trait similar to the outcome CHD associates with an outlier and is included in the multivariable analysis of multiple exposures against coronary CHD, then all the putative exposures will be dropped from the model. In the analyses presented we manually removed traits that came up as candidate pleiotropic pathways but were, in fact, synonymous with or closely related to the outcome. Third, we note that heterogeneity does not necessarily arise only because of pleiotropy, for example the non-collapsibility of odds ratios will introduce heterogeneity automatically which cannot be adjusted away through the TRYX approach. Many other mechanisms exist that can lead to bias in MR, as has been described in detail elsewhere. Fourth, SNPs can appear to be outliers not through being pleiotropic, but through other mechanisms, such as population stratification (association of alleles with phenotypes being confounded by ancestral population), canalization (developmental compensation to a genetic change) 2, 43, or the influence on phenotype being changeable across the life course 44. Fifth, since MR-TRYX uses the resource from MR-Base, it is recommended that the user acknowledge the limitation and restriction of MR-Base 10. For example, the population should be the same for the exposure (or the candidate traits) and the outcome traits to avoid mis-estimation of the magnitude of the association. The users should consider modifying their analyses when the limitation indicated above are avoidable. Sixth, in the case of a binary outcome, there may be parametric restrictions on the conditional causal odds ratio in our multivariable MR model where the exposure effect is linear in the exposure on the log odds ratio scale 45. However, the two-stage estimator with a logistic second-stage model still yields a valid test of the causal null hypothesis 45.

In this study, we demonstrated the use of MR-TRYX through four examples of identifying putative pathways. In the first empirical example (SBP on CHD), we illustrated the validity of MR-TRYX to detect the traits that possibly influence the disease outcome. Apart from SBP, MR-TRYX also detected well established risk factors for CHD including adiposity, cholesterol levels and standing height. An interesting finding of this example is that headache related traits (e.g. experience of pain due to headache and self-reported status of ibuprofen intake) were identified as candidate traits, which may influence the original association. In support of the putative finding for self-reported ibuprofen use associating with CHD, we also found that pain experienced in the last month (headache) and self-reported migraine were associated with lower risk of CHD (OR per 1 SD: 0.33; 95% CI: 0.12, 0.89 and Beta= 0.02; 95% CI: 0.0004, 0.65, respectively). A previous study reported shared genetic risk between headache (migraine) and CHD, suggesting a potential role of migraine in vascular mechanisms 46. An alternative mechanism that could give rise to this association is that the effect of pain on lower CHD risk is entirely mediated through the use of medications such as aspirin that have known protective effects on CHD.

The example of urate and CHD demonstrated the benefit of the adjustment method showing that the noise due to pleiotropy was substantially reduced after correcting for the effect of candidate traits. The presence of hypothyroidism and self-reported levothyroxine sodium intake status were identified as putative risk factors for risk of CHD, which is consistent with previous clinical trial studies: thyroid dysfunction is associated with the overall coronary risk 47, which can be reversed by levothyroxine therapy 48. In the education – BMI example, we showed that increased alcohol intake and slower usual walking pace may influence the obesity of individuals. These identified traits have been reported as possible risk factors for higher BMI and obesity 49, 50. Additionally, the example of sleep duration and risk of schizophrenia suggested coeliac disease and body composition as putative risk factors for schizophrenia. A number of observational studies suggested that schizophrenia is linked with body composition 51 and coeliac disease 52. MR of binary exposures is often difficult to interpret because the instrument effects are on liability to disease, not the presence or absence of the disease. Hence, the association between coeliac disease and schizophrenia may be better interpreted as an indication of shared disease aetiology. Nevertheless, this is a valuable finding since the causal effect of those putative risk factors on risk of schizophrenia has not been investigated using an MR approach. Therefore, our example illustrates how outliers can be used to identify alternative pathways, opening the door for hypothesis-free MR approaches and a network-based approach to disease.

In conclusion, we have shown a new method to deal with the bias from horizontal pleiotropy, and to identify putative risk factors for outcomes in a more directed manner than typical hypothesis-free analyses, by exploiting outliers. Heterogeneity is widespread across MR analyses and so we are tapping into a potential new reservoir of information for understanding the aetiology of disease. The strategy is a departure from previous ones dealing with pleiotropy – we have shown that enlarging the problem by searching across all traits for a better understanding of a specific exposure-outcome hypothesis can be fruitful.

**Author contributions**

YC, GDS and GH conceived the study and developed the statistical analysis plan. YC and GH developed the model and methods. YC, GDS and GH prepared the first draft of manuscript. YC, PCH, TRG, JZ, APM, GDS, and GH contributed to the writing of the manuscript. All authors reviewed and agreed on the manuscript.

**Competing interests**

The authors declare that they have no conflict of interest.

**Data availability**

The data that support the findings of this study are available from MR-Base ([www.mrbase.org](http://www.mrbase.org)).

## **References**

1. Holmes MV, Ala-Korpela M, Davey Smith G. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. *Nat Rev Cardiol* **14**, 577-590 (2017).

2. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International Journal of Epidemiology* **32**, 1-22 (2003).

3. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* **23**, R89-98 (2014).

4. Johnson T, Uk S. Efficient calculation for multi-SNP genetic risk scores. In: *Technical report, The Comprehensive R Archive Network* (ed^(eds) (2013).

5. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. *Am J Epidemiol* **178**, 1177-1184 (2013).

6. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International Journal of Epidemiology* **44**, 512-525 (2015).

7. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* **40**, 304-314 (2016).

8. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* **46**, 1985-1998 (2017).

9. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet*, (2018).

10. Hemani G*, et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, e34408 (2018).

11. Corbin LJ*, et al.* BMI as a Modifiable Risk Factor for Type 2 Diabetes: Refining and Understanding Causal Estimates Using Mendelian Randomization. *Diabetes* **65**, 3002-3007 (2016).

12. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *Plos Genet* **13**, (2017).

13. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med* **36**, 1783-1802 (2017).

14. Bowden J*, et al.* Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol*, (2018).

15. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* **50**, 693-698 (2018).

16. Bakker M, Wicherts JM. Outlier removal, sum scores, and the inflation of the Type I error rate in independent samples t tests: the power of alternatives and recommendations. *Psychol Methods* **19**, 409-427 (2014).

17. Hemani G*, et al.* Automating Mendelian randomization through machine learning to construct a putative causal map of the human phenome. *bioRxiv*, 173682 (2017).

18. Bateson W. *The methods and scope of genetics*. Cambridge University Press (2014).

19. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* **37**, 658-665 (2013).

20. Bowden J*, et al.* Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol* **47**, 1264-1278 (2018).

21. Bowden J, Hemani G, Davey Smith G. Detecting individual and global horizontal pleiotropy in Mendelian randomization: a job for the humble heterogeneity statistic? *Am J Epidemiol*, (2018).

22. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? *Phys Ther* **81**, 1464-1469 (2001).

23. Wasserstein RL, Lazar NA. The ASA's Statement on p-Values: Context, Process, and Purpose. *Am Stat* **70**, 129-131 (2016).

24. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single sample and two-sample summary data settings. *bioRxiv*, (2018).

25. Bennett DA, Holmes MV. Mendelian randomisation in cardiovascular research: an introduction for clinicians. *Heart* **103**, 1400-1407 (2017).

26. White J*, et al.* Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. *Lancet Diabetes Endocrinol* **4**, 327-336 (2016).

27. Tyrrell J*, et al.* Height, body mass index, and socioeconomic status: mendelian randomisation study in UK Biobank. *BMJ* **352**, i582 (2016).

28. Kaskie RE, Graziano B, Ferrarelli F. Schizophrenia and sleep disorders: links, risks, and management challenges. *Nat Sci Sleep* **9**, 227-239 (2017).

29. Anderson EL*, et al.* Education, intelligence and Alzheimer’s disease: Evidence from a multivariable two-sample Mendelian randomization study. *bioRxiv*, (2018).

30. Kleber ME*, et al.* Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. *J Am Soc Nephrol* **26**, 2831-2838 (2015).

31. Strom D, Dudovitz R, Guerrero LR, Wong MD. The Link between Education and Health: It Is Not What You Know, but Whom You Know. *J Gen Intern Med* **30**, S277-S278 (2015).

32. Bockerman P*, et al.* Does higher education protect against obesity? Evidence using Mendelian randomization. *Prev Med* **101**, 195-198 (2017).

33. Cohen AK, Rai M, Rehkopf DH, Abrams B. Educational attainment and obesity: a systematic review. *Obes Rev* **14**, 989-1005 (2013).

34. Okbay A*, et al.* Genome-wide association study identifies 74 loci associated with educational attainment. *Nature* **533**, 539-542 (2016).

35. Locke AE*, et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206 (2015).

36. Zhu ZH*, et al.* Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat Commun* **9**, (2018).

37. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol* **181**, 251-260 (2015).

38. Corbin LJ*, et al.* BMI as a Modifiable Risk Factor for Type 2 Diabetes: Refining and Understanding Causal Estimates Using Mendelian Randomization. *Diabetes* **65**, 3002-3007 (2016).

39. Hartwig FP, Borges MC, Horta BL, Bowden J, Davey Smith G. Inflammatory Biomarkers and Risk of Schizophrenia A 2-Sample Mendelian Randomization Study. *Jama Psychiat* **74**, 1226-1233 (2017).

40. Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* **40**, 755-764 (2011).

41. Jiang L*, et al.* Constrained Instruments and their Application to Mendelian Randomization with Pleiotropy. *bioRxiv*, 227454 (2017).

42. Visscher PM*, et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation. *Am J Hum Genet* **101**, 5-22 (2017).

43. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. *Int J Epidemiol* **33**, 30-42 (2004).

44. Tan Q, Jacobsen R, Sorensen M, Christiansen L, Kruse TA, Christensen K. Analyzing age-specific genetic effects on human extreme age survival in cohort-based longitudinal studies. *Eur J Hum Genet* **21**, 451-454 (2013).

45. Vansteelandt S, Bowden J, Babanezhad M, Goetghebeur E. On Instrumental Variables Estimation of Causal Odds Ratios. *Stat Sci* **26**, 403-422 (2011).

46. Winsvold BS*, et al.* Shared genetic risk between migraine and coronary artery disease: A genome-wide analysis of common variants. *Plos One* **12**, (2017).

47. Rodondi N*, et al.* Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA* **304**, 1365-1374 (2010).

48. Fadeyev VV, Sytch J, Kalashnikov V, Rojtman A, Syrkin A, Melnichenko G. Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease. *Endocr Pract* **12**, 5-17 (2006).

49. Cho Y, Shin SY, Won S, Relton CL, Davey Smith G, Shin MJ. Alcohol intake and cardiovascular risk factors: A Mendelian randomisation study. *Sci Rep* **5**, 18422 (2015).

50. Williams PT, Thompson PD. The relationship of walking intensity to total and cause-specific mortality. Results from the National Walkers' Health Study. *Plos One* **8**, e81098 (2013).

51. Sugawara N*, et al.* Body composition in patients with schizophrenia: Comparison with healthy controls. *Annals of general psychiatry* **11**, 11 (2012).

52. Ludvigsson JF, Osby U, Ekbom A, Montgomery SM. Coeliac disease and risk of schizophrenia and other psychosis: a general population cohort study. *Scand J Gastroenterol* **42**, 179-185 (2007).

**Figure legends**


**Figure 1.  Conceptual framework of the study: Illustration of identifying novel factors that influence the original association.** (a) Where (gy) is the total effect of the SNP on the outcome, (gx) is the SNP-exposure effect, (xy) is the exposure-outcome effect as estimated through MR analysis from the non-outlier SNPs, (gp) is the SNP-candidate trait effect and (py) is the causal effect of the candidate trait on the outcome. (b) The open circles represent valid instruments and the slope of the dotted line represents the causal effect estimate of the exposure on the outcome. The closed circle represents an outlier SNP which influences the outcome, through two independent pathways (py).(c) One way in which the red SNP can exhibit a larger influence on the outcome than expected given its effect on the exposure is if it influences the outcome additionally through another pathway (horizontal pleiotropy). (d) Using the MR-Base database of GWAS summary data for hundreds of traits we can search for ‘candidate traits’ with which the outlier SNP has an association. (e) Instruments excluding the original outlier SNP are obtained for each candidate trait, LASSO-based multivariable MR is used to prune the candidate traits to avoid redundancy, and the causal influence of each of those independent candidate traits on the outcome can subsequently be estimated. This allows us to identify new traits that putatively influence the outcome, and adjust the SNP-outcome associations for pleiotropic pathways in the original exposure-outcome model.

**Figure 2. Simulations comparing methods across different scenarios.** We evaluated three scenarios: confounding pleiotropy, horizontal pleiotropy, and mediated pleiotropy (columns of graphs, with DAGs illustrating the scenarios. See methods for full details). The x axis of each graph represents the proportion of variants used to instrument x that exhibit pleiotropic effects. Typically, 30 instruments were simulated directly for x but this varies across scenarios where necessary. The y axis of the first row of graphs represents the proportion of simulations that lead to unbiased effect estimates of x on y. The y axis of the second row of graphs represents the sensitivity and specificity of the analysis across the simulations, where the area under the receiving operating curve (AUROC) represents the ability of the method to distinguish between simulations in which the causal effect of x on y is either null or not null. For all graphs, higher y axis values are better. Seven methods are evaluated at each simulation. ‘Raw’ = IVW random effects estimates applied to all detected instruments; ‘Removed’ = either all outliers are removed, or only outliers detected to associate with a candidate trait; ‘MVMR’ = multivariable MR using either candidate traits detected to associate with any instrument or using only candidate traits associated with outlier instruments; ‘Adjusted’ = Adjusting SNP-outcome associations for candidate traits applied either only to variants detected to be outliers, or all variants regardless of outlier status.

**Figure 3. Manhattan plot to visualise the causal associations between candidate exposures and hypothesised outcome.** This represents the number of traits associated with outliers. The plot is stratified by phenotype category and, within each group, we present the results related to the candidate traits identified. Along the X axis, different phenotype groups are shown in different colours. The Y axis presents log transformed P value for each trait. Filled circles in each category indicate the evidence of association between candidate traits and exposure or outcome (p < 0.05). (A) Empirical analysis 1: Systolic blood pressure (mmHg) and coronary heart disease (log odds). (B) Empirical analysis 2: Urate (mg/dl) and coronary heart disease (log odds). (C) Empirical analysis 3: Sleep duration (hour/night) and schizophrenia (log odds). (D) Empirical analysis 4: Years of schooling (years) and body mass index (kg/m2).

**Figure 4. Scatter plot for the exposure-outcome association adjusting the SNP effects on the candidate traits.** The arrow indicates changes in the SNP effect after conditioning on the effect of candidate traits on the outcome. The candidate traits that influence the association of the original exposure and the original outcome were listed in the box. (A) Empirical analysis 1: Systolic blood pressure (mmHg) and coronary heart disease (log odds). (B) Empirical analysis 2: Urate (mg/dl) and coronary heart disease (log odds). (C) Empirical analysis 3: Sleep duration (hour/night) and schizophrenia (log odds). (D) Empirical analysis 4: Years of schooling (years) and body mass index (kg/m2).


**Figure 1.**




**Figure 2.**



**Figure 3.**



**Figure 4.**



**Table 1. Candidate traits associated with both exposure and outcome.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outlier SNPs** | **Nearest gene** | **Category** | **Phenotypes** 1 | **N SNPs** 2 | **Beta (95% CI)** 3 |
| **Empirical analysis 1. Systolic blood pressure (mmHg) and coronary heart disease (log odds)** | | | | | |
| rs3184504 | *SH2B3* | Early development | Birth weight of first child | 40 | -0.312 (-0.498, -0.126) |
| Anthropometric measures | Standing height | 577 | -0.208 (-0.264, -0.152) |
| Lipid | LDL cholesterol  HDL cholesterol  Total cholesterol | 78  86  86 | 0.393 (0.290, 0.497)  -0.172 (-0.288, -0.055)  0.378 (0.271, 0.484) |
| rs9349379 | *PHACTR* | Medications | Self-reported status of ibuprofen intake | 2 | -16.726 (-37.262, 3.811) |
| **Empirical analysis 2. Urate (mg/dl) and coronary heart disease (log odds)** | | | | | |
| rs653178 | *ATXN2* | Early development | Birth weight of first child  Birth weight | 31  40 | 0.347 (0.065, 0.628)  -0.312 (-0.498, -0.126) |
| Anthropometric measures | Comparative height size at age 10  Hip circumference  Impedance of arm (left)  Standing height | 357  275  305  577 | -0.248 (-0.342, -0.154)  0.131 (0.030, 0.231)  -0.263 (-0.380, -0.145)  -0.208 (-0.264, -0.152) |
| Lipid | HDL cholesterol  LDL cholesterol  Total cholesterol | 78  86  86 | 0.393 (0.290, 0.497)  -0.172 (-0.288, -0.055)  0.378 (0.271, 0.484) |
| Disease | hypothyroidism/myxoedema (Self-reported) | 77 | 0.847 (0.211, 1.483) |
| Smoking | Past tobacco smoking | 41 | -0.265 (-0.500, -0.029) |
| Medications | Treatment/medication: levothyroxine sodium | 51 | 1.231 (0.270, 2.191) |
| rs642803 | *OVOL1* | Anthropometric measures | Waist circumference | 218 | 0.458 (0.352, 0.563) |
| **Empirical analysis 3. Sleep duration (hour/night) and schizophrenia (log odds)** | | | | | |
| rs7764984 | *HIST1H2BJ* | Disease | Malabsorption/coeliac disease (self-reported) | 11 | -8.401 (-12.842, -3.961) |
| rs13107325 | *SLC39A8* | Anthropometric measures | Impedance of leg (left) | 282 | 0.179 (0.047, 0.311) |
| Memory | Prospective memory result | 2 | 4.493 (1.851, 7.135) |
| **Empirical analysis 4. Years of schooling (years) and body mass index (kg/m2)** | | | | | |
| rs6882046 | *LINC00461* | Drinking | Alcohol intake frequency | 31 | 0.347 (0.065, 0.628) |
| rs4800490 | *NPC1* | Drinking | Alcohol intake frequency | 31 | 0.347 (0.065, 0.628) |
| Exercise | Usual walking pace | 22 | -1.595 (-2.364, -0.825) |
| rs8049439 | *ATXN2L* | Drinking | Alcohol intake frequency | 31 | 0.347 (0.065, 0.628) |

SNP, single nucleotide polymorphism; VLDL, very low-density lipoprotein; HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol; N SNPs, number of SNPs; CI, confidence interval.

1 Candidate traits that are associated with outliers (p < 5 x 10-8) and both exposure and outcome are listed. The listed traits were used in the adjusted model to investigate whether they are associated with CHD. 2 The number of SNPs used for two sample MR analysis of candidate traits on the outcome. 3 The results were presented as IVW beta coefficient (95% CI), derived from two sample MR analyses.

**Table 2. The results of empirical analyses with different IV estimators derived from different methods.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | **Estimates (95% CIs)** | | | |
| **Methods** | | **All variants** | **Removing outliers** | **Removing candidate outliers** | **Adjustment for candidate outliers** |
| **Empirical analysis 1. Systolic blood pressure (mmHg) and coronary heart disease (log odds)** | | | | | |
|  | Heterogeneity (*Q*)1 | 682.7  (N SNPs = 157) | 312.1  (N SNPs = 150) | 448.7  (N SNPs = 155) | 567.6  (N SNPs = 157) |
|  | IVW random effects | 1.761 (1.474, 2.104) | 1.876 (1.655, 2.125) | 1.797 (0.558, 5.789) | 1.706 (1.449, 2.008) |
|  | Egger random effects | 2.641 (1.490, 4.679) | 2.951 (1.970, 4.419) | 2.206 (0.314, 15.472) | - |
|  | Intercept | 0.980 (0.969, 0.992) | 0.990 (0.982, 0.998) | 0.996 (0.988, 1.004) | - |
|  | Weighted median | 1.770 (1.528, 2.050) | 1.782 (1.539, 2.065) | 1.765 (0.576, 5.403) | - |
|  | Weighted mode | 1.770 (1.264, 2.479) | 1.726 (1.218, 2.447) | 1.740 (0.600, 5.043) | - |
| **Empirical analysis 2. Urate (mg/dl) and coronary heart disease (log odds)** | | | | | |
|  | Heterogeneity (*Q*) | 81.6  (N SNPs = 24) | 20.7  (N SNPs = 21) | 33.4  (N SNPs = 22) | 44.1  (N SNPs =24) |
|  | IVW random effects | 1.081 (0.996, 1.174) | 1.054 (1.008, 1.103) | 1.062 (1.057, 1.122) | 1.070 (0.992, 1.155) |
|  | Egger random effects | 0.952 (0.846, 1.071) | 1.008 (0.937, 1.084) | 0.990 (0.910, 1.077) | - |
|  | Intercept | 1.015 (1.003, 1.027) | 1.006 (0.998, 1.014) | 0.992 (0.984, 1.000) | - |
|  | Weighted median | 1.019 (0.961, 1.081) | 1.016 (0.958, 1.078) | 1.017 (0.961, 1.077) | - |
|  | Weighted mode | 1.028 (0.975, 1.084) | 1.022 (0.966, 1.082) | 1.025 (0.970, 1.083) | - |
| **Empirical analysis 3. Sleep duration (hour/night) and schizophrenia (log odds)** | | | | | |
|  | Heterogeneity (*Q*) | 204.8  (N SNPs = 36) | 54.1  (N SNPs = 30) | 121.4  (N SNPs = 34) | 147.7  (N SNPs =36) |
|  | IVW random effects | 1.184 (0.573, 2.445) | 1.289 (0.828, 2.008) | 1.215 (0.674, 2.192) | 1.181 (0.634, 2.197) |
|  | Egger random effects | 0.866 (0.056, 13.383) | 2.428 (0.485, 12.158) | 2.363 (0.254, 21.955) | - |
|  | Intercept | 1.004 (0.968, 1.042) | 0.991 (0.969, 1.013) | 0.991 (0.963, 1.020) | - |
|  | Weighted median | 1.276 (0.774, 2.104) | 1.249 (0.746, 2.090) | 1.250 (0.761, 2.052) | - |
|  | Weighted mode | 1.327 (0.679, 2.593) | 1.504 (0.728, 3.105) | 1.428 (0.702, 2.904) | - |
| **Empirical analysis 4. Years of schooling (years) and body mass index (kg/m2)** | | | | | |
|  | Heterogeneity (*Q*) | 211.9  (N SNPs = 59) | 101.9  (N SNPs = 56) | 101.9  (N SNPs = 56) | 197.8  (N SNPs =59) |
|  | IVW random effects | -0.272 (-0.386, -0.158) | -0.232 (-0.314, -0.150) | -0.232 (-0.314, -0.150) | -0.265 (-0.377, -0.153) |
|  | Egger random effects | 0.013 (-0.677, 0.703) | -0.404 (-0.910, 0.102) | -0.404 (-0.910, 0.102) | - |
|  | Intercept | -0.005 (-0.017, 0.007) | 0.003 (-0.005, 0.011) | 0.003 (-0.005, 0.011) | - |
|  | Weighted median | -0.209 (-0.307, -0.111) | -0.217 (-0.315, -0.119) | -0.217 (-0.315, -0.119) | - |
|  | Weighted mode | -0.141 (-0.413, 0.131) | -0.127 (-0.405, 0.151) | -0.127 (-0.405, 0.151) | - |

N SNPs, number of single nucleotide polymorphisms; 95% CIs, 95% confidence intervals; IVW, Inverse variance weighted. 1 Heterogeneity amongst the estimates were assessed based on contribution of individual variant to Cochran’s statistic.